Dosing of AR-15512 for dry eye begins in next step of COMET program

The first subject has been dosed in the phase 3 registrational COMET-3 study investigating AR-15512 for the treatment of dry eye disease, according to a press release from Aerie Pharmaceuticals.
The randomized, double-masked, vehicle-controlled multicenter clinical study will enroll approximately 460 participants with dry eye disease who will be randomly assigned to receive either AR-15512 0.003% or AR-15512 vehicle as a drop twice daily in each eye for 3 months. Tear production, measured by unanesthetized Schirmer’s test, is the primary efficacy assessment, with a secondary measure of

The first subject has been dosed in the phase 3 registrational COMET-3 study investigating AR-15512 for the treatment of dry eye disease, according to a press release from Aerie Pharmaceuticals.
The randomized, double-masked, vehicle-controlled multicenter clinical study will enroll approximately 460 participants with dry eye disease who will be randomly assigned to receive either AR-15512 0.003% or AR-15512 vehicle as a drop twice daily in each eye for 3 months. Tear production, measured by unanesthetized Schirmer’s test, is the primary efficacy assessment, with a secondary measure of